Haleon plc (HLN) - Net Assets
Based on the latest financial reports, Haleon plc (HLN) has net assets worth $16.46 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($32.57 Billion) and total liabilities ($16.12 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore HLN asset base for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.46 Billion |
| % of Total Assets | 50.52% |
| Annual Growth Rate | -8.15% |
| 5-Year Change | -37.86% |
| 10-Year Change | N/A |
| Growth Volatility | 14.05 |
Haleon plc - Net Assets Trend (2019–2025)
This chart illustrates how Haleon plc's net assets have evolved over time, based on quarterly financial data. Check Haleon plc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Haleon plc (2019–2025)
The table below shows the annual net assets of Haleon plc from 2019 to 2025. For live valuation and market cap data, see Haleon plc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $16.46 Billion | +1.42% |
| 2024-12-31 | $16.22 Billion | -3.02% |
| 2023-12-31 | $16.73 Billion | +1.65% |
| 2022-12-31 | $16.46 Billion | -37.85% |
| 2021-12-31 | $26.48 Billion | +0.98% |
| 2020-12-31 | $26.22 Billion | -4.34% |
| 2019-12-31 | $27.41 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Haleon plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 444.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $27.80 Billion | 169.54% |
| Common Stock | $89.84 Million | 0.55% |
| Total Equity | $16.40 Billion | 100.00% |
Haleon plc Competitors by Market Cap
The table below lists competitors of Haleon plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ameriprise Financial Inc
NYSE:AMP
|
$40.38 Billion |
|
Erste Group Bank AG
VI:EBS
|
$40.39 Billion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
$40.49 Billion |
|
Block, Inc
NYSE:XYZ
|
$40.64 Billion |
|
Sysco Corporation
NYSE:SYY
|
$40.33 Billion |
|
Legrand SA
PA:LR
|
$40.29 Billion |
|
LEGRAND UNSP.ARD 1/5 EO 4
F:LRC0
|
$40.25 Billion |
|
ArcelorMittal SA
AS:MT
|
$40.19 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Haleon plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 16,166,000,000 to 16,396,129,908, a change of 230,129,908 (1.4%).
- Net income of 1,630,468,421 contributed positively to equity growth.
- Dividend payments of 598,588,286 reduced retained earnings.
- Share repurchases of 639,667,874 reduced equity.
- Other comprehensive income increased equity by 11,081,000,000.
- Other factors decreased equity by 11,243,082,353.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.63 Billion | +9.94% |
| Dividends Paid | $598.59 Million | -3.65% |
| Share Repurchases | $639.67 Million | -3.9% |
| Other Comprehensive Income | $11.08 Billion | +67.58% |
| Other Changes | $-11.24 Billion | -68.57% |
| Total Change | $- | 1.42% |
Book Value vs Market Value Analysis
This analysis compares Haleon plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.73x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.68x to 2.73x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $5.92 | $9.95 | x |
| 2020-12-31 | $5.66 | $9.95 | x |
| 2021-12-31 | $5.71 | $9.95 | x |
| 2022-12-31 | $3.54 | $9.95 | x |
| 2023-12-31 | $3.59 | $9.95 | x |
| 2024-12-31 | $3.52 | $9.95 | x |
| 2025-12-31 | $3.64 | $9.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Haleon plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.94%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.11%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.99x
- Recent ROE (9.94%) is above the historical average (6.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 2.40% | 7.72% | 0.24x | 1.31x | $-2.08 Billion |
| 2020 | 4.38% | 11.58% | 0.29x | 1.31x | $-1.47 Billion |
| 2021 | 5.27% | 14.56% | 0.28x | 1.31x | $-1.25 Billion |
| 2022 | 6.49% | 9.76% | 0.31x | 2.13x | $-573.10 Million |
| 2023 | 6.32% | 9.28% | 0.33x | 2.05x | $-611.60 Million |
| 2024 | 8.92% | 12.84% | 0.33x | 2.12x | $-174.60 Million |
| 2025 | 9.94% | 15.11% | 0.33x | 1.99x | $-9.14 Million |
Industry Comparison
This section compares Haleon plc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $177,350,140
- Average return on equity (ROE) among peers: -87.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Haleon plc (HLN) | $16.46 Billion | 2.40% | 0.98x | $40.34 Billion |
| Aurora Cannabis Inc (ACB) | $1.68 Million | 0.08% | 0.00x | $172.06 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $2.69 Million |
| Akebia Ther (AKBA) | $635.93 Million | -27.03% | 0.57x | $340.21 Million |
| Alkermes Plc (ALKS) | $18.84 Million | -398.98% | 9.71x | $7.49 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-151.17 Million | 0.00% | 0.00x | $1.64 Billion |
| Amphastar P (AMPH) | $364.36 Million | -1.57% | 0.41x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $5.21 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -174.05% | 9.57x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $178.10 Million | 21.52% | 0.09x | $196.52 Million |
| ANI Pharmaceuticals Inc (ANIP) | $15.83 Million | -300.23% | 1.30x | $1.79 Billion |
About Haleon plc
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; an… Read more